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Abstract
Obtaining informed consent is a key protection that should be afforded universally to people using health
services and the basis around which any participation in clinical trials is built.
Randomized controlled effectiveness studies are necessary to answer key questions in hospice and palliative
care, in order to help systematically improve the quality of care. In order to be properly generalizable, such trials
need to have broad inclusion criteria to reflect the population most likely to be affected by the condition. The
inclusion of patients who are seriously ill, and therefore potentially vulnerable, requires careful exploration of
ethical and legal principles that underpin informed consent.
Specific challenges in obtaining informed consent for randomised clinical trials (RCTs) in clinically unstable
populations such as hospice and palliative care include higher rates of people with impaired cognitive capacity
as well as interventional studies in clinical situations which may present as a sudden change in condition. None
of these challenges is unique to hospice and palliative care research, but the combination and frequency with
which they are encountered require systematic and considered solutions.
This article outlines five different ethically valid consent approaches and discusses their applicability to hospice
and palliative care research trials. These include: consent by the patient (at the time of enrolment, in advance of
the study, or delayed until after the study has commenced); a proxy (or legally authorised representative); or a
consent waiver. Increased use of the less traditional modes of informed consent may lead to greater participation
rates in hospice and palliative care trials, thereby improving the evidence base more rapidly in part by better
reflecting the population served and hence improving generalizability.
Introduction
Obtaining informed consent is a key protection thatshould be afforded universally to people using health
services and the basis aroundwhich any participation in clinical
trials is built. Randomized controlled effectiveness studies are
necessary to answer key questions in hospice and palliative
care, in order to help systematically improve the quality of care.
In order to be properly generalizable, such trials need to have
broad inclusion criteria to reflect the population most likely to
be affected by the condition. The inclusion of patients who are
seriously ill, and therefore potentially vulnerable, requires
careful exploration of ethical and legal principles that underpin
informed consent. Challenges in obtaining informed consent for
randomized clinical trials (RCTs) in clinically unstable popula-
tions such as hospice and palliative care include higher rates
of people with impaired cognitive capacity as well as inter-
ventional studies in clinical conditions that arise suddenly.
Neither of these challenges is unique to hospice and palliative
care research, but the combination and frequency with which
they are encountered require systematic and considered so-
lutions. This paper outlines five different ethically valid con-
sent mechanisms and discusses their applicability to hospice
and palliative care research trials. These include consent by
the patient (at the time of enrollment, in advance of the study,
or delayed until after the study has commenced); a proxy (or
legally authorized representative); or a consent waiver. In-
creased use of less-traditional modes of informed consent,
such as proxy or early consent, may lead to greater partici-
pation rates in hospice and palliative care trials, thereby
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improving the evidence base more rapidly, in part by better
reflecting the population served and hence improving gen-
eralizability.
Research in hospice and palliative care is essential to inform
improvements in the quality of the care offered to those with
serious and life-limiting illnesses. People in palliative care and
hospice (inpatient, ambulatory, and community) services are
keen to participate in clinical research at rates far higher than
other clinical disciplines1 as part of a legacy, to help to make
sense of their current condition, and to improve care for
people in the future.2 Palliative care researchers must be es-
pecially vigilant not to exploit such good will.1
Ethical and legal frameworks must be incorporated into
trial design and conduct. Even with these in place, sound
clinical research is required to enhance scientific knowledge,
and must be methodologically rigorous, ensure fair subject
selection, have a favorable risk-benefit ratio, be indepen-
dently reviewed, and guarantee respect for the enrolled
subjects.3
Ethical Frameworks of Informed Consent
The key goal of clinical research is to improve the quality of
medical care by developing generalizable knowledge gained
from studying a small sample of subjects. In the pursuit of this
knowledge, research subjects are inevitably exposed to some
risks they otherwise would not encounter. It is therefore im-
portant that any potential harm is minimized and any find-
ings used as widely as possible.
Informed consent is one of the most important ways per-
sons are afforded protection; such consent is underpinned by
respect for participants’ autonomy. Cases of unethical re-
search performed on human subjects without their knowl-
edge or consent have been well documented.4,5 Informed
consent allows the subject with decision making capacity to
weigh up the potential personal risks and benefits in the
context of the purpose of the research to determine whether
involvement is acceptable and personally meaningful.
The International Conference on Harmonisation Good
Clinical Practice (ICH GCP)6 provides consensus guidelines
on the design, conduct, safety, and reporting of clinical trials.
The guidelines outline the responsibilities and expectations of
all participants involved in the conduct of a clinical trial. The
process of obtaining informed consent as outlined in ICH
GCP guidelines ensures (1) the potential participant gets ob-
jective information from the investigator or trial staff without
coercion or undue influence to participate; (2) the investigator
or trial staff have appropriate credentials and skills relevant to
the potential participant and his or her concerns; (3) infor-
mation delivered is in an appropriate setting and in an un-
hurried manner; and (4) ample opportunity for the potential
participant to ask questions.
Though not mandated by ICH GCP, the participant may
have a family member or support person present who can ask
questions or take information away to discuss with a family
member or primary care doctor before deciding whether or
not to participate.7,8
Challenges in Palliative Care Research
There are no consent issues unique to palliative care and
not found in other clinical research settings, for example in
emergency medicine or geriatric medicine. However, there
are scenarios that occur more frequently than in other clinical
disciplines or are otherwise amplified by clinical research in
the hospice and palliative care setting. Obtaining informed
consent for participation in hospice and palliative care clinical
trials is an ongoing challenge faced by researchers.9,10 The
reasons for this are complex and multifaceted and influenced
by the nature of the research itself as well as by patient/par-
ticipant, provider, and systems issues.
In terms of research topics, palliative care research may
focus on specific times in a person’s illness when consent is
unable to be obtained, e.g., investigations into terminal re-
spiratory secretions or the development of delirium, or on
unpredictable events, e.g., first presentation of a bowel
obstruction.9 There are sensitivities around introducing a
study that is exploring a symptom or clinical condition in
people with a life-limiting illness if the participant may not
have full knowledge of his or her condition or prognosis, does
not acknowledge his or her condition,6 or does not currently
have the condition being studied but is quite likely to develop
it in the foreseeable future.
At the patient/participant level, challenges in providing
informed consent may include, but are not limited to (1) im-
paired or fluctuating decision making capacity (in the hospice
and palliative setting this can occur due to the illness itself,
e.g., brain tumors, delirium, psychoactive medications); (2)
decreased levels of consciousness in the terminal phase (last
hours or days of life); or (3) a sense of being in an increasingly
dependent relationship with health professionals in general
because of progressive frailty.
Inmore advanced disease, participants fatigue easily and can
find it difficult to concentrate for long periods on processes like
consent, especially if the information is new and complex.9 This
population is predominantly comprised of older adults whose
mentation and physical well-being may be deteriorating.
At the provider level, clinicians may facilitate engagement
or create barriers. Ways in which clinicians become gate-
keepers include where the clinician makes the decision not to
inform the patient/participant that a trial is available or fails
to provide a patient with objective information regarding a
study in an effort to ‘‘protect’’ him or her. This creates a sit-
uation where the patient/participant who still is antonomous
and has decision making capacity is unable to make an in-
formed choice for his or herself.11,12
Informed Consent in Palliative Care Research
There are different mechanisms for informed consent that
can potentially be applied to palliative care research to ensure
nonexploitation and protection of subjects. In this paper, five
mechanisms of consent are discussed. The paper is limited to
studies of interventions that aim to impact symptom control
and quality of life for someone utilizing a palliative care service.
The paper does not consider studies ofmedications unrelated to
a person’s condition, such as phase I studies of a new medica-
tion’s first use in patients for a condition they don’t have. Such
studies require more detailed data, given the greater possibility
of harm,where the person participates simply because he or she
is dying but does not have the index condition.13
The five consent mechanisms under consideration involve
the participant (1) at the time of enrollment, (2) in advance of
having the index condition or commencing the study, or (3)
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deferred to a time after the study has commenced; another
person, (4) ‘person responsible’ or ‘proxy;’ or no consent, (5)
waived consent.
Participant’s informed consent at the time
of enrollment
This mechanism should be utilized wherever possible and
can be achieved in the majority of palliative care clinical
studies immediately prior to the time of enrolment in the
study. A key principle is that complexity and presentation of
information has to be in the context of this person’s ability to
make decisions (competence), with a view to ensuring that his
or her key concerns are addressed in providing information.
This is largely independent of age but not of education.14 The
ability to make informed decisions about participating in
clinical research is generally deemed to be present if an indi-
vidual possesses all of these characteristics:
 understanding of the issues involved in the decision
including the research protocol and the risks and ben-
efits of participation or nonparticipation
 rational ability to manipulate this information
 appreciation of the information in the context of pa-
tient’s situation
 demonstrable consistency in this process
 evidence of a voluntary and uncoerced choice15
A number of tools have been validated in an attempt to
refine and standardize the processes of determining a pa-
tient’s capacity to consent to participate in research. An ex-
ample is the MacArthur Competence Assessment Tool.16
However, recent reviews of such instruments have found that,
while they can aid clinicians to make decisions regarding
capacity, the results are variable and in the end, capacity de-
cisions are largely a matter of clinical judgment. Un-
fortunately, determining decisional capabilities in many
mildly cognitively impaired people remains challenging and
is approached with a high degree of variability.17–20
During the consent process, the researcher is continually
determining the potential participant’s understanding of the
information and his or her capacity then to provide fully in-
formed consent. Consideration should be given to allowing
the consent process to occur over several short sessions rather
than one longer session. Additionally, as the life-limiting ill-
nesses progress and a potential participant’s performance
status declines, the researcher should regularly assess the
person’s willingness to continue to participate in the research
throughout the entire research project, and not just prior to the
commencement of the study.
In any clinical setting, participants may be eager to please
their clinicians, creating a milieu where exploitation could
potentially occur, despite the fact that the person obtaining
consent is a third party. In palliative care there may be a
perception that a clinical trial brings hope for improved
health, which may be an unrealistic expectation. Despite these
difficulties, a participant’s own informed consent remains the
gold standard.
Participant’s informed consent in advance
of having the index condition
Advanced consent here is defined as the consent of subjects
prior to a predictable or potential loss of capacity21 or where
there may be a need to initiate therapy rapidly without the
ability to engage meaningfully in a conversation about the trial.
Informed consent takes place before the onset of either cognitive
decline or the emergence of the condition of interest, yet close
enough to enrollment to allow information that is relevant and
salient to the condition of interest to be discussed.21 Advanced
consent can facilitate research in palliative care without the re-
liance on surrogate or proxy decision making at the time an
emotionally distressing event has occurred andhas beenused in
studies of critical care management after planned surgery
whereby patients are consented prior to induction of anaes-
thesia.2 Advanced consent for autopsy has also been used, es-
pecially to advance research into dementia, which aids relatives
in knowing the prior wishes of the deceased.3,24
After advanced consent has been obtained, asking the pa-
tient/participant to nominate a person to act as his or her
proxy during the study period further enhances processes to
safeguard the best interests of the participant. The proxy can
continue to act on the patient/participant’s behalf if testa-
mentary capacity is lost between consent and initiating the
study or during the course of the study. Some researchers
have had this person also sign a consent form at the same time
as the potential participant and confirm the participant’s ad-
vanced consent at the time of trial participation if the patient/
participant is unable to. Indeed, given that capacity may
change during a study, it has been suggested that the relevant
proxy be involved in all palliative care research.25
Advanced consent may also be used where a person is at
high risk of a condition and there is the need to begin therapy
without delay. In a study of delirium in hospitalized people
with AIDS, advanced consent was used to recruit subjects
who were not delirious but allowed participation if they
subsequently developed delirium.26 People who have had an
episode of delirium are at high risk of another episode and
could provide advanced consent. Advanced consent has also
been used in studies of terminal respiratory secretions when
the person is most likely unconscious.27,28 Such an approach
necessitated informed consent to be obtained from a relatively
large number of people compared with those eventually
randomized.
Malignant bowel obstruction. It is possible to identify a
high-risk group (patients with previous subacute bowel ob-
struction or patients with widespread peritoneal cancer) who
could potentially participate in a phase III study of pharma-
cological management if a bowel obstruction occurred.29
Given that the majority of patients/participants in this setting
are likely to present to the emergency department, at which
time discussion about potential study participation may be
difficult, this is a group appropriate for considering advanced
consent. Only on presentation would the person be random-
ized to a particular intervention arm. This allows rapid initi-
ation of therapy in the trial protocol. In cases of bowel
obstruction the participant will likely be able to confirm
consent. In a recently completed study of such patients, 112
people were randomized, of whom 21 were among the 63
people who had given advanced consent.
Concerns have been raised regarding a patient’s ability to
truly consider the implications of research when he or she
does not have a firsthand understanding of the condition. This
is an overwhelming issue, and one way to resolve it is limiting
consent to people who have had the index condition resolve
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and yet are at high likelihood of recurrence of delirium or
bowel obstruction.
Participant’s informed consent deferred
to a time after the study has commenced
Deferred consent is where the participant is enrolled in the
study without consent and then, when able, may provide
consent. The data collected until that time point may then be
utilized as the person commences to participate in the
study.30,31 This is an approach used in emergency and critical
care research,32,33 where there is a higher probability that
study procedures will have been completed prior to an ability
to obtain consent. In emergency and critical care research,
excluding people from whom consent could not earlier be
obtained will jeopardize the conduct of the study.34 There
are probably few palliative care research scenarios in which
deferred consent has a place, as this consent mechanism fails
to afford protection from overinclusion in research and may
jeopardize the voluntary nature of participation.
‘Person responsible’ or ‘proxy’ consent
When a potential participant is unable to give informed
consent, a proxy or person responsible can be used. National
guidelines in the United States, United Kingdom, other parts
of Europe, and Australia guide how such consent can be
given.35–42 A proxymay not necessarily be the person’s next of
kin; this is a statutory concept. In the United States a proxy is
defined in federal regulations as a Legally Authorized Re-
presentative (LAR) who is ‘‘an individual or judicial or other
body authorized under applicable law to consent on behalf of
the prospective subject to the subject’s participation in the
procedure(s) involved in the research.’’43 Complementary
state-based laws outlining who can serve as an LAR and the
circumstances under which this can occur are often not clear.43
The European Directive relating to good clinical practice in
clinical trials states that the vulnerable should ‘‘be included in
clinical trials only where there are grounds for expecting the
administering of the medicinal product would be of direct
benefit to the participant, thereby outweighing the risks.’’37
However, the sign-off for the European Directive has not been
completed by all countries and, even with sign-off, individual
countries’ legislative frameworks define proxy consent and
conditions differently, or are not clear.
Proxy consent has been utilized in dementia research and
has been determined to be acceptable to both participants and
their proxies.21,39 Delirium research is also suited to consid-
eration of proxy consent given absent or fluctuating capacity
to consent. Delirium research that is unable to utilize a ‘person
responsible’ consent results in participant populations that
don’t represent delirium patients as a whole and hence limit
generalizability when translating into clinical practice.44 A
successful use of proxy consent was in an RCT using best
evidence pharmacological management of delirium and
comparing risperidone with haloperidol or placebo.45 This
study acknowledges delirium is potentially reversible and if
testamentary capacity is regained, participant consent is ac-
tively sought before continued participation in the study.
In the setting when the participant may not have capacity
to consent, it is important to consider whether the research
question has sufficient merit and whether the risks involved
are justified by the proposed benefits.39 The thresholds
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considered appropriate by ethics committees or institutional
review boards may differ from those for research where the
participants can consent for themselves. Another key princi-
ple to consider in this setting is that it is not possible to con-
duct effective research only in adults who have capacity to
consent for conditions such as delirium, as such findings
could not be generalized.35,37,41
To successfully undertake studies utilizing ‘person re-
sponsible’ consent, systems must be in place that can objec-
tively determine capacity, consider the merits of the question,
and have a local institutional review board or ethics com-
mittee skilled in its consideration—or a specific independent
tribunal that reviews trials of this nature.1 There also remains
the need to ensure that if a ‘person responsible’ or ‘proxy’ is
used, he or she is even more informed than a competent po-
tential participant, given what is asked of the proxy.
Waived consent
Much debate has occurred about conducting a clinical trial
without consent, with approval of the study as a whole by the
local ethics committee only. Precedents exist for waived
consent, including studies to evaluate interventions for car-
diac arrests and acute brain injuries.46 There is unlikely to be a
study in palliative care that warrants waiving consent by ei-
ther the potential participant or his or her proxy.
Table 1 provides a comparison of the five mechanisms of
consent and their ability to meet the principles required for
valid informed consent. Participant consent either at the time
of enrollment or in advance can meet all the principles, with
the one concern being with individuals yet to experience the
condition having a different understanding from those who
are consented having experienced the index condition. Be-
cause of this concern, advanced consent should be reserved
for situations where patient/participant consent at time of
enrollment would not be possible for the index condition for
the reasons outlined in detail above.
Deferred and waived consent do not meet most of the re-
quirements for informed consent and are unlikely to be valid
mechanisms in palliative care research, as the clinical sce-
narios that warrant their use don’t occur, and alternative
consent approaches can be applied in most study situations.
Proxy consent meets the principles of informed consent in
relation to the proxy, but not by the participant who lacks the
ability to exercise autonomy at this time in his or her illness.
On balance, it is important that high-quality evidence is
available for conditions where the participant is unable to
provide consent at the time or in advance such as with new-
onset delirium, that clear guidelines exist to inform the design
of clinical trials utilizing proxy consent, and how proxy con-
sent can best be obtained.
Legal Frameworks that Complement
the Ethical Frameworks
Consideration of the mechanisms of informed consent that
meet internationally recognized legal principles is crucial to
match the ethical underpinnings of research. Failure to obtain
proper informed consent for participation in research has
been grounds for common law negligence and malpractice
claims.47 There is general agreement that there is a legal duty
to properly inform potential research participants of the risks
and benefits of the research; the scope and extent of this duty
vary depending on jurisdiction. In the United States three
different standards exist. There are two material risk stan-
dards: one requires physicians to provide all the information
that a hypothetical reasonable patient would consider sig-
nificant in making a decision; the other material risk standard
defines duty to disclose information by reference to what an
actual specific patient would consider material. The third
material risk standard, the malpractice standard, requires
physicians to provide information that a reasonably prudent
physician would disclose in the same circumstances. The
malpractice standard is based therefore on the accepted
practice of the medical profession.
In Australia and the United Kingdom, recent case law has
seen a shift from the standard of the prudent physician (Bolam
Principle) to what a reasonable patient would expect.48 To
establish a malpractice case in addition to establishing breach
of the duty of disclosure, research participants need to show
injury and causation. Had the researcher engaged in a satis-
factory informed consent process in which a reasonable per-
son would have consented to the research? While litigation
brought by research participants is rare, the incidence has
been increasing with utilization of novel claims of actions and
class actions, apart from the common law grounds.49
Conclusions
The challenge of research in palliative care amplifies several
aspects of informed consent, given the nature of the populations
and the studies, that can inform better quality of care. As well
as the legal issues, the knowledge, attitudes, and beliefs of
patients/participants, their families, and health care providers
influence informed consent. These challenges are not insur-
mountable, but have for too long contributed to the limited
number of controlled clinical trials in palliative care. Participant
consent at time of enrollment, advance consent by participant,
and ‘‘proxy’’ consent all meet the ethical requirements of in-
formed consent and can be used in palliative care clinical trials.
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